Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Prosser, Lisa A. ; Bridges, Carolyn Buxton ; Uyeki, Timothy M. ; Hinrichsen, Virginia L. ; Meltzer, Martin I. ; Molinari, Noelle-Angelique M. ; Schwartz, Benjamin ; Thompson, William W. ; Fukuda, Keiji ; Lieu, Tracy A.
• Description:
  We estimated cost-effectiveness of annually vaccinating children not at high risk with inactivated influenza vaccine (IIV) to range from US $12,000 per quality-adjusted life year (QALY) saved for children ages 6-23 months to $119,000 per QALY saved for children ages 12-17 years. For children at high risk (preexisting medical conditions) ages 6-35 months, vaccination with IIV was cost saving. For children at high risk ages 3-17 years, vaccination cost $1,000-$10,000 per QALY. Among children notat high risk ages 5-17 years, live, attenuated influenza vaccine had a similar cost-effectiveness as IIV. Risk status was more important than age in determining the economic effects of annual vaccination, and vaccination was less cost-effective as the child's age increased. Thus, routine vaccination of all children is likely less cost-effective than vaccination of all children ages 6-23 months plus all other children at high risk.
• Subjects:
  Adolescent Child Child, Preschool Cost-Benefit Analysis Humans Infant Influenza Vaccines Mass Vaccination Quality Of Life Research Sensitivity And Specificity Vaccines, Inactivated

  More +
• Source:
  Emerg Infect Dis. 12(10):1548-1558.
• Document Type:
  Journal Article
• Volume:
  12
• Issue:
  10
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:d557978e2a303825e99951d21f312fa00d35f958c1ad13cd29ac98bd0d97c7e5
• Download URL:
  https://stacks.cdc.gov/view/cdc/7899/cdc_7899_DS1.pdf
• File Type:
  [PDF - 461.07 KB ]